The company generates revenue through the sale of its directSTIM™ system, a DBS solution designed to eliminate surgical failures and non-responder patients, fully manufactured and assembled in Switzerland. Aleva has developed a proprietary neurostimulation platform based on microDBS technology with unique microfabricated devices enabling target-specific stimulation and optimization of current therapies.
Cyborg Score Rationale
Aleva has secured regulatory approval (CE Mark in 2019) and meaningful funding ($42M total as of 2025), with proven medical device technology and early commercialization. However, limited public revenue data, small employee base (~21 staff), and absence of major recent funding announcements since December 2021 suggest moderate growth trajectory and execution risk for scaling.
Top Insights
Proprietary MEMS-based directional DBS technology offers target-specific stimulation with microsurgical precision, differentiating from conventional non-directional systems
CE Mark approval achieved in December 2019 enables European commercialization, but U.S. regulatory pathway and FDA approval status remain unclear
Founded as EPFL spin-off in 2008 with deep academic neuroscience heritage, reducing core technology risk but creating potential commercialization/scaling challenges
Joint venture with DIXI Medical (Adept Neuro, June 2019) in epilepsy-focused SEEG electrodes suggests diversification beyond DBS but execution status post-2021 unclear
Named Competitors
DBS Portfolio — Deep brain stimulation systems for Parkinson's and neurological disorders
DBS Portfolio (Infinity, Proclaim) — Deep brain stimulation systems for movement and neurological disorders
DBS Portfolio (Percept, Vantage) — Deep brain stimulation and neuromodulation systems
Recent Developments
(December 2021) Series E funding round led by CIP Merchant Capital for undisclosed amount
(July 2022) European MRI approval for deep brain stimulation system
(September 2021) Recruitment of first patient into PMCF (Post-Market Clinical Follow-up) study
(December 2019) CE Mark obtained for directSTIM™ DBS system; raised $8 million private equity funding
Open the full interactive Aleva Neurotherapeutics report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.